Product information:
| Product name |
Nitrendipine tablets |
| Shelf Life |
3 Years |
| Specification |
20mg 10*10/box |
| Storage |
Keep in dark and sealed |
Pharmacokinetics:
The oral absorption of this product is good, but there is obvious first pass effect. The protein binding rate was 98%. Early studies reported that T1 / 2 was 2 hours. Recent studies reported that T1 / 2 was between 10 and 22 hours due to the use of more sensitive measuring equipment. After oral administration, the concentration of the drug reached the peak value about 1.5 hours. The systolic blood pressure began to decrease 30 minutes after oral administration, and the diastolic blood pressure began to decrease after 60 minutes. The antihypertensive effect reached the maximum at 1 to 2 hours after oral administration and lasted for 6 to 8 hours. 70% of its metabolites are excreted by kidney and 8% by feces. The serum concentration and elimination half-life of liver disease patients increased.
Pharmacology and Toxicology:
1. This product is dihydropyridine calcium channel blocker.
2. This product can inhibit the transmembrane calcium influx of vascular smooth muscle and myocardium, but it mainly acts on vessels, so its vascular selectivity is strong.
3. This product causes the dilation of coronary artery, renal arteriole and other systemic blood vessels, resulting in antihypertensive effect. No carcinogenic effect was found in rats after oral administration of nifedipine for two years. The results of mutagenesis in vivo were negative.
Indication:
Hypertension, heartache.
Adverse reactions:
Headache and flushing are rare. Rare have dizziness, nausea, hypotension, foot and ankle edema, angina attack, transient hypotension. Allergic hepatitis, rash and even exfoliative dermatitis may occur in allergic patients.
Matters needing attention:
1. A few cases may have increased serum alkaline phosphatase.
2. When the liver function is not complete, the blood drug concentration can be increased, and when the renal function is not complete, the influence on the pharmacokinetics is small.
3. The vast majority of patients can only tolerate mild hypotension after taking this drug, but some patients may have severe systemic hypotension symptoms. This reaction often occurs during the initial adjustment of dosage or when increasing the dosage, especially when combined with beta blockers. Therefore, blood pressure should be measured regularly during taking this product.
4. It has been proved that a very small number of patients, especially those with severe coronary artery stenosis, have an increased incidence of angina pectoris or myocardial infarction during the course of taking the drug or increasing the dose. The mechanism is still unclear. Therefore, ECG should be taken regularly during taking this product.
5. A small number of patients receiving beta blockers may develop heart failure after taking the drug, and patients with aortic stenosis have a greater risk.
Audited Supplier 
){kind=link}